CryoLife on the brink after product recall and SEC (Securities and Exchange Commission) probe
This article was originally published in Clinica
Executive Summary
Throughout the toughest times for tissue implants specialist CryoLife this summer, the company has always been able to draw confidence from one absolute: the FDA had not ordered a product recall.